This article is more than 5 years old. Information may no longer be current.
RetinoStat pre-clinical data ‘encouraging’
Click Here to Manage Email Alerts
A system that uses genes to block the formation of new blood vessels in the retina has shown “encouraging” results in laboratory testing, according to the system’s developer.
Oxford BioMedica’s RetinoStat is being evaluated for delivering two angiogenesis genes to the retina: endostatin and angiostatin. Results of pre-clinical studies were presented last week at the Association for Research in Vision and Ophthalmology meeting, the company said in a press release.
According to Oxford BioMedica, both versions of RetinoStat were safe and well tolerated and both achieved the two main efficacy endpoints, with a statistically significant improvement in all scores. In an “industry standard model of age-related macular degeneration,“ areas of choroidal neovascularization were reduced by 50% to 60% (P < .05) and blood vessel leakage was reduced by 24% to 26% (P < .05), the press release said.
“Similar improvements in these parameters in patients with AMD may translate into a significant and sustained improvement in visual acuity,” the company said in the release. Oxford BioMedica hopes to start clinical trials with RetinoStat in wet AMD in 2006-2007.